Cargando…
IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
SIMPLE SUMMARY: Despite progress, acute myeloid leukemia (AML) remains one of the deadliest cancer diseases. The identification of novel molecular targets may allow developing innovative and alternative treatment options for AML. Using public data from genome-edited cancer cells, we identified facto...
Autores principales: | Liss, Franziska, Frech, Miriam, Wang, Ying, Giel, Gavin, Fischer, Sabrina, Simon, Clara, Weber, Lisa Marie, Nist, Andrea, Stiewe, Thorsten, Neubauer, Andreas, Burchert, Andreas, Liefke, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917770/ https://www.ncbi.nlm.nih.gov/pubmed/33673123 http://dx.doi.org/10.3390/cancers13040764 |
Ejemplares similares
-
Combined cistrome and transcriptome analysis of SKI in AML cells identifies SKI as a co-repressor for RUNX1
por: Feld, Christine, et al.
Publicado: (2018) -
The CpG Island-Binding Protein SAMD1 Contributes to an Unfavorable Gene Signature in HepG2 Hepatocellular Carcinoma Cells
por: Simon, Clara, et al.
Publicado: (2022) -
AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023) -
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022) -
AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)